In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sapphire Therapeutics licenses Novo Nordisk ghrelin compound

Executive Summary

Sapphire Therapeutics (formerly Rejuvenon Corp.; in-licenses development candidates for cancer and metabolic disorders) has licensed from Novo Nordisk worldwide exclusive rights to a small-molecule compound related to the ghrelin pathway, which it will first develop for postoperative ileus (POI), or constipation following surgery.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies